semaglutide cardiovascular outcomes 2025 news oral indication in High-Risk Type 2 Diabetes: Benefit Confirmed in the SOUL Trial ACC 2025: Oral Semaglutide Reduces – Canadian Perspectives 2025 Whiteboard on

366 DDX17 The DEAD-box RNA helicase p72 (DDX17) has been shown to act as transcriptional co-activator for ER

The benefits in ASCVD risk reduction with GLP-1RA are evidenced by 14% risk reduction in cardiovascular mortality with an NNTB of 207 to prevent one event, 13% MACE reduction with an NNT of 67 to prevent one event and 12% risk reduction in stroke with an NNT of 335 to prevent one event, along with their favourable safety profile of 6% increased overall adverse events

GHRP-6 produces potent GH release but also significantly stimulates hunger through ghrelin pathway activation

Thyroid and Pancreas Warnings Some early studies raised concerns about thyroid tumors and pancreatitis, though these havent been proven in people

Its not a finished story, and its not meant for anything beyond controlled lab work, but thats exactly what makes it worth studying further

, .